is tirzepatide a diabetic drug FDA says shortage of GLP-1 over FDA approves new version of

Standard Dosing: 250-500 mcg Per Day The clinical trial tested doses up to 500 mcg daily with no dose-limiting toxicities

Wegovy vision loss lawsuits can now be filed or transferred to IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (MDL Number 3163)

Clinical trials primarily focused on individuals with obesity or overweight plus comorbidities

Research out of Sweden and the University of North Carolina suggest weekly doses of the drugs active ingredient, semaglutide, correlated with reduced drinking and alcohol-related hospitalization in participants with alcoholism